Combative U.S. FDA panel votes against Biogen Alzheimer's drug

The FDA still could decide to approve the drug, aducanumab, making it the first new Alzheimer’s treatment in decades. Several of the 11 panel members expressed resentment that the FDA’s early view of aducanumab – which was made public on Wednesday – was biased toward a favorable outcome for Biogen. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.